BioSpace News Archive

Microplate systems are used extensively in research and diagnostics, which require quick and high-throughput analysis of the patients.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global kidney fibrosis treatment market is expected to expand at a healthy rate from 2021 to 2031.

Taiwanese firm CancerFree Biotech Ltd. has developed a breakthrough for patients with stage 2 solid tumor.

The inaugural ZAODX World Conference on Early Detection of Cancer was successfully held at the Chimelong International Conference Center in Guangzhou from July 15-17, 2022.

AbbVie announced that the European Commission has approved RINVOQ®, an oral therapy, for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation, as indicated by elevated C-reactive protein and/or magnetic resonance imaging, who have responded inadequately to nonsteroidal anti-inflammatory drugs.

ACM Biolabs announced that the first subject has been dosed in the first–in–human Phase 1 trial of its clinical candidate vaccine, ACM-001, a 2nd generation adjuvanted SARS-CoV-2 spike protein vaccine with broad protection against variants of concerns, including delta and omicron demonstrated in a variety of preclinical studies.

Bionomics Limited, a global, clinical stage biopharmaceutical company, released its Quarterly Activities and ASX Appendix 4C Cashflow Reports.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce significant new and expanded sales of the company’s companion animal products.

HistoIndex, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current conventional histological scoring system, in quantifying treatment-associated changes in Nonalcoholic Steatohepatitis (NASH).

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.